These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 31553250)

  • 41. Ceftobiprole medocaril.
    Méndez R; Latorre A; González-Jiménez P
    Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):25-27. PubMed ID: 35488820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.
    Anderson SD; Gums JG
    Ann Pharmacother; 2008 Jun; 42(6):806-16. PubMed ID: 18477729
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection.
    Cumper C; Richards C; Smart J; Litherland K; Jones M
    J Med Microbiol; 2023 Oct; 72(10):. PubMed ID: 37791651
    [No Abstract]   [Full Text] [Related]  

  • 44. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin.
    Chambers HF
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():17-22. PubMed ID: 16524424
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
    Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
    J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
    Jones ME
    Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Ceftaroline fosamil in community-acquired and nosocomial pneumonia].
    Calbo E; Zaragoza R
    Enferm Infecc Microbiol Clin; 2014 Mar; 32 Suppl 2():38-43. PubMed ID: 24702978
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro activity of ceftaroline and ceftobiprole against methicillin-resistant Staphylococcus aureus with decreased susceptibility to vancomycin isolated in paediatric patients.
    Carnesecchi G; Lobello R; Liggieri L; Palmero C; Pescetto L; Morelli P; Castagnola E; Bandettini R
    J Chemother; 2018; 30(6-8):338-341. PubMed ID: 30375268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MRSA--the tip of the iceberg.
    Appelbaum PC
    Clin Microbiol Infect; 2006 Apr; 12 Suppl 2():3-10. PubMed ID: 16524422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model.
    Barnea Y; Navon-Venezia S; Kuzmenko B; Artzi N; Carmeli Y
    Eur J Clin Microbiol Infect Dis; 2014 Mar; 33(3):325-9. PubMed ID: 24030718
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ceftobiprole medocaril: a new generation beta-lactam.
    Del Pozo JL; Patel R
    Drugs Today (Barc); 2008 Nov; 44(11):801-25. PubMed ID: 19180259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options.
    Welte T; Pletz MW
    Int J Antimicrob Agents; 2010 Nov; 36(5):391-400. PubMed ID: 20724119
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and effectiveness of Ceftaroline Fosamil in patients with pneumonia: a systematic review and meta-analysis.
    Sotgiu G; Aliberti S; Gramegna A; Mantero M; Di Pasquale M; Trogu F; Saderi L; Blasi F
    Respir Res; 2018 Oct; 19(1):205. PubMed ID: 30352588
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
    Saravolatz LD; Stein GE; Johnson LB
    Clin Infect Dis; 2011 May; 52(9):1156-63. PubMed ID: 21467022
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016-2017).
    Pfaller MA; Flamm RK; Duncan LR; Shortridge D; Smart JI; Hamed KA; Mendes RE; Sader HS
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):304-313. PubMed ID: 30808530
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High Rate of Ceftobiprole Resistance among Clinical Methicillin-Resistant
    Morroni G; Brenciani A; Brescini L; Fioriti S; Simoni S; Pocognoli A; Mingoia M; Giovanetti E; Barchiesi F; Giacometti A; Cirioni O
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30275082
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.
    Murthy B; Schmitt-Hoffmann A
    Clin Pharmacokinet; 2008; 47(1):21-33. PubMed ID: 18076216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ceftobiprole: a new beta-lactam antibiotic.
    Stein RA; Goetz RM; Ganea GM
    Int J Clin Pract; 2009 Jun; 63(6):930-43. PubMed ID: 19490203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ceftaroline (Teflaro): a new cephalosporin.
    Belavic JM
    Nurse Pract; 2011 Nov; 36(11):12-3. PubMed ID: 22008594
    [No Abstract]   [Full Text] [Related]  

  • 60. Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole.
    Lima B; Bodeau S; Quinton MC; Leven C; Lemaire-Hurtel AS; Bennis Y
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.